ClinicalTrials.gg
CompletedNCT06425055ALPESTRIA-1Updated Feb 9, 2026

Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)

A Phase 2 interventional study of Vonafexor in Alport Syndrome, sponsored by Enyo Pharma. Completed at 13 sites in 3 countries. Open to participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
16 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Nephritis, Hereditary with a site in United States — 5 open to participants now, 8 under way, none of them phase 3. Nephritis, Hereditary · United States.

Enrollment
9th of 11
26 · median 60
Started
2024
the only one that year
Phase 2
7 of 19
2 open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
Enyo Pharma

Among the 19 studies in Nephritis, Hereditary with a site in United States, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 7 in phase 2, and was the 16th registered.

Nephritis, Hereditary

39 studies on the registry are indexed under Nephritis, Hereditary; 15 are open to participants now.

Browse Nephritis, Hereditary studies →

Open to participants now

5 of the 19 studies in Nephritis, Hereditary with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Nephritis, Hereditary studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 16 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Nephritis, Hereditary with a site in United States, or all of them as a file.
02

Study summary

This study is a proof-of-concept trial of vonafexor safety, its effects on kidney function in subjects with at risk of progression Alport syndrome.

Read the detailed description

This is a multicenter study and several clinical sites and countries will be involved.

This single arm, fixed dose escalation, open-label, non-randomized study will evaluate three dose levels of vonafexor on safety, tolerability and their effect on kidney function and renal biomarkers in 20 patients with AS at risk of progression.

The total duration of study for a participant will be up to 40 weeks and include a screening period, a treatment period of 24 weeks and a follow-up period of 12 weeks.

03

Conditions studied

  • Alport Syndrome

Browse trials for

04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed (also for legal representatives, as applicable in the US for under eighteen patients).
  • Has confirmed diagnosis of Alport syndrome: clinical diagnosis (haematuria, family history, hearing loss, ocular change) OR a kidney showing glomerular basement membrane abnormalities consistent with AS, AND Genetic confirmation of AS.
  • Has between ≥ 30 and \< 90 ml/min/1.73m2.
  • Has increased albuminuria criteria i.e. UACR ≥ 300 mg/g.
  • If on an angiotensin converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB), should be on a stable well tolerated treatment during at least the 60 days prior D1.
  • If on Sodium-Glucose Transport Protein 2 (SGLT2), should be on stable well tolerated treatment with SGLT2 during at least 60 days prior D1.
  • If patient has a history of arterial hypertension, should be on stable anti-hypertensive therapy for at least 60 days prior to D1 and deemed controlled by the investigator at screening and D1.
  • Sexually active female subjects of and sexually mature male subjects must use two acceptable effective methods of for the entire duration of the study and for at least 6 weeks after last dose.
  • Has negative results for surface antigen (HBsAg), virus (HCV) antibody, and (HIV).
  • Is able to understand all study procedures in the informed consent form (ICF) and willing to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Is an employee of a site, clinical research organization, vendor, or sponsor involved with this study.
  • Is pregnant or breastfeeding.
  • Has participated in any drug study within 60 days prior to D1.
  • Any illness within 30 days before D1 or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety.
  • Any history of active within the last 1 year before D1.
  • Any other condition or circumstance that, in the opinion of the investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety and well-being.
  • Has a history of an allergic condition that required the prescription of an emergency epinephrine injection (such as the EpiPen® Auto-Injector).
  • Any prohibited co-medications within 30 days prior D1.
  • Has or AST above near normal (>1.5×) at baseline.
  • Are at high risk for atherosclerotic cardiovascular disease (ASCVD) risk, with an LDL-C level > 160 mg/dL (4.15 mmol/L) and subjects at intermediate risk for ASCVD risk, with a LDL-C level > 190 mg/dL (4.91 mmol/L).
  • Has moderate or severe hepatic impairment ( score B or C).
  • Is taking /5 inhibitors or inducers.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Single arm fixed dose escalation

    This is a single arm fixed dose escalation with three dose levels of vonafexor, all QD.

    Drug: Vonafexor

Interventions

  • DrugVonafexor

    * One tablet of a low dose of vonafexor QD from Day 1 to Week 4 * One tablet of a medium dose of vonafexor QD from Week 5 to Week 8 * One tablet of a high dose of vonafexor QD from Week 9 to Week 24

    Also known as: EYP001a

06

What researchers measure

Primary outcomes

  1. Number of Treatment-Emergent Adverse Event (TEAE)

    To assess the safety and tolerability of vonafexor

    Time frame: From first dose of treatment until 2 weeks after last dose of treatment, i.e assessed up to 26 weeks

Secondary outcomes

  1. Change in eGFR

    To determine the on with the off-treatment effect of three dose levels of vonafexor on renal function

    Time frame: During on-treatment (assessed up to 24 weeks) and off-treatment periods (assessed up to 36 weeks) compared to baseline

  2. Vonafexor plasma concentrations

    To determine vonafexor plasma concentrations levels

    Time frame: During on-treatment period, assessed up to 24 weeks

Other outcomes

  1. Change in albuminuria

    To determine the effect of vonafexor on and off treatment on exploratory renal biomarkers

    Time frame: During on-treatment (assessed up to 24 weeks) and off-treatment periods (assessed up to 36 weeks) compared to baseline

  2. Change in proteinuria

    To determine the effect of vonafexor on and off treatment on exploratory renal biomarkers

    Time frame: During on-treatment (assessed up to 24 weeks) and off-treatment periods (assessed up to 36 weeks) compared to baseline

  3. Change in Neutrophil Gelatinase Associated Lipocalin (NGAL)

    To determine the effect of vonafexor on and off treatment on exploratory renal biomarkers

    Time frame: During on-treatment (assessed up to 24 weeks) and off-treatment periods (assessed up to 36 weeks) compared to baseline

07

Study locations

13 sites
  • Dr Eric Wallace - University of Alabama
    Birmingham, Alabama 35294, United States
  • Dr Anjay Rastogi - UCLA Health, David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • Dr Arnold Silva - Boise Kidney & Hypertension
    Boise, Idaho 83703, United States
  • Dr Suneel Udani - NANI Research
    Hinsdale, Illinois 60521, United States
  • Dr Tingting Li - Washington University
    St Louis, Missouri 63110, United States
  • Dr James Simon - Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Dr Ankit Mehta - Renal Disease Research Institute
    Dallas, Texas 75126, United States
  • Pr Claire Rigothier - CHU De Bordeaux
    Bordeaux, 33076, France
  • Dr Moglie Le Quintrec - Hopital Lapeyronie
    Montpellier, 34090, France
  • Pr. Bertrand Knebelmann - Necker Enfants Malades
    Paris, 75015, France
  • Fundacio Puigvert
    Barcelona, 08025, Spain
  • Hospital Virgen de la Arrixaca
    El Palmar, 30120, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
08

References and documents

Publications

  • Rheault MN. Treatment Approaches for Alport Syndrome. J Am Soc Nephrol. 2026 Jan 1;37(1):172-179. doi: 10.1681/ASN.0000000897. Epub 2025 Sep 12. PubMed 40938675 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underline published results might be shared upon request with researchers who provide a methodologically sound proposal and to achieve objectives as set in the approved proposal. IPD will be shared deidentified and from 3 months and ending 5 years following article publication.

Supporting information: Study protocol, Statistical analysis plan

Time frame: From 3 months and ending 5 years following article publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Sep 2025, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2024
First posted
May 22, 2024
StartActual
Aug 1, 2024
Primary completionActual
Sep 4, 2025
CompletionActual
Nov 20, 2025
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06425055
Lead sponsor
Enyo Pharma
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Aug 1, 2024
Primary completion
Sep 4, 2025
Completion
Nov 20, 2025
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion